Why the study?
VISTA is a key target for cancer treatment due to its broad expression and role in adaptive immune checkpoint resistance, but its mechanisms in antitumor immunity are not fully understood.
Anti-VISTA therapy overcomes adaptive resistance to PD-1/CTLA-4 blockade in a colorectal cancer model by modulating CD8+ T-cell quiescence and enhancing antigen presentation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Su et al. (2025) studied Colorectal cancer. Anti-VISTA therapy vs. Anti-PD-1/CTLA-4 alone was evaluated on Tumor growth and rejection.
Synapse has enriched 4 related papers. Consider them for comparative context: